Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyClover Health Kadcyla Prior Auth Policy | OpenPaye…
    Ask Trek AI about this page
    CurrentClover HealthPolicy 2471-A

    Standard Medicare Part B Management Kadcyla

    Customize your policy alerts

    Sign up for clover_health Policy 2471-A alerts

    Get alerted when Policy 2471-A changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of Kadcyla for Medicare members with covered breast cancer, HER2-mutated non-small cell lung cancer, and HER2-positive salivary gland tumors.

    Policy Summary
    PayerClover Health
    PolicyStandard Medicare Part B Management Kadcyla
    Policy CodePolicy 2471-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with HER2 status available upon request and document that all applicable coverage criteria are met.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsStandard authorization period
    HER2 statusRequired documentation
    2FDA-approved breast cancer categories
    3Specified compendial-use categories
    Single agentRequired treatment approach

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Covered Indications and Authorization Criteria

    Breast cancer

    Covered for breast cancer when the applicable indication and single-agent treatment requirement are met.

    Breast cancer indication

    • Metastatic or recurrent breast cancer: Subsequent treatment of HER2-positive metastatic or recurrent breast cancer using Kadcyla as a single agent.12 months
    • Residual or nonresponsive early breast cancer: HER2-positive breast cancer with no response to preoperative systemic therapy using Kadcyla as a single agent.12 months
    • Adjuvant early breast cancer: Adjuvant treatment of HER2-positive early breast cancer using Kadcyla as a single agent.up to 12 months

      Adjuvant breast cancer treatment is limited to a total of 12 months during continuation therapy.

    • Small asymptomatic brain metastases: Initial treatment of small asymptomatic brain metastases in HER2-positive breast cancer using Kadcyla as a single agent.12 months

    Non-small cell lung cancer

    Covered for subsequent treatment of HER2-mutated non-small cell lung cancer when ALL criteria are met.

    HER2-mutated non-small cell lung cancer

    • Disease extent: The disease is recurrent, advanced, or metastatic.
    • Single-agent use: The requested medication will be used as a single agent.
    • No progression on HER2-targeted therapy: The member has not experienced disease progression on a HER2-targeted drug, such as Enhertu or Kadcyla.

    Salivary gland tumor

    Covered for treatment of HER2-positive salivary gland tumors when all stated requirements are met.

    HER2-positive salivary gland tumor

    • Disease status: The salivary gland tumor is recurrent, unresectable, or metastatic.

      At least one listed disease status must apply.

    • Single-agent use: Kadcyla is used as a single agent.

    Continuation therapy

    Continuation authorization may be granted for all members, including new members, when ALL criteria are met.

    Continuation of therapy

    • Currently receiving treatment: The member is currently receiving treatment with Kadcyla.
    • Covered diagnosis: Kadcyla is being used to treat a diagnosis or condition listed in the coverage criteria section.
    • Clinical benefit

      • Tolerability: There is no evidence of unacceptable toxicity while on the current regimen.
      • Disease control:

    Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Kadcyla requests for covered breast cancer, HER2-mutated non-small cell lung cancer, and HER2-positive salivary gland tumor indications. Approval is contingent on meeting the applicable criteria and having no exclusions to the prescribed therapy.

    • Submit documentation supporting the applicable indication and coverage criteria.
    • Authorization may be granted for up to 12 months, as specified for the indication.
    Documentation Required

    HER2-Mutated NSCLC Criteria

    For HER2-mutated non-small cell lung cancer, request authorization only when the disease is recurrent, advanced, or metastatic; Kadcyla will be used as a single agent; and the member has not experienced disease progression on a HER2-targeted drug such as Enhertu or Kadcyla.

    Therapy Background

    Kadcyla (ado-trastuzumab emtansine) is a HER2-directed antibody-drug conjugate used as a single agent for specified indications. Covered uses include FDA-approved metastatic and early HER2-positive breast cancer, as well as selected uses in recurrent or stage IV HER2-positive breast cancer, HER2-mutated non-small cell lung cancer, and HER2-positive recurrent, unresectable, or metastatic salivary gland tumors.

    Policy Definitions

    HER2 status
    DefinitionHuman epidermal growth factor receptor 2 (HER2) status used to identify HER2-positive disease or HER2 mutation-associated disease for covered indications.
    Covered applicationsHER2 status is used for covered breast cancer, non-small cell lung cancer with HER2 mutations, and HER2-positive salivary gland tumor indications.
    DocumentationHER2 status must be available upon request for all submissions.
    Benefit from therapy
    DefinitionBenefit from therapy requires no evidence of unacceptable toxicity and no evidence of disease progression on the current regimen.
    TolerabilityThere must be no evidence of unacceptable toxicity while the member is on the current regimen.

    Treatment Line Terminology

    Subsequent treatment

    Metastatic or recurrent breast cancer: Subsequent treatment of HER2-positive metastatic or recurrent breast cancer with Kadcyla as a single agent.

    Prior trastuzumab and a taxane are specified for the FDA-approved metastatic indication.

    Adjuvant

    Adjuvant early breast cancer: Adjuvant treatment of HER2-positive early breast cancer with residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment, using Kadcyla as a single agent.up to 12 months

    Second-line

    Subsequent HER2-mutated NSCLC:

    HER2 Biomarker Requirements

    HER2
    Required biomarkerHER2-positive.
    Applicable indicationsRequired for metastatic and early breast cancer coverage.
    DocumentationHER2 status must be available upon request for all submissions.
    HER2 (ERBB2) mutation
    Required findingHER2 (ERBB2) mutation present.
    Applicable indicationRequired for non-small cell lung cancer coverage.
    Disease contextThe non-small cell lung cancer must be recurrent, advanced, or metastatic.

    Covered Kadcyla Regimens

    RegimenIndicationCoverageAuthorization period
    Kadcyla (ado-trastuzumab emtansine) as a single agentHER2-positive breast cancer: subsequent treatment of metastatic or recurrent disease; breast cancer with no response to preoperative systemic therapy; adjuvant treatment of early breast cancer; or initial treatment of small asymptomatic brain metastasesCovered12 months; up to 12 months for adjuvant early breast cancer
    Kadcyla (ado-trastuzumab emtansine) as a single agentNon-small cell lung cancer with HER2 (ERBB2) mutations that is recurrent, advanced, or metastatic, without disease progression on a HER2-targeted drugCovered12 months
    Kadcyla (ado-trastuzumab emtansine) as a single agentRecurrent, unresectable, or metastatic HER2-positive salivary gland tumorsCovered12 months
    Policy Summary
    PayerClover Health
    PolicyStandard Medicare Part B Management Kadcyla
    Policy CodePolicy 2471-A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit prior authorization requests with HER2 status available upon request and document that all applicable coverage criteria are met.
    SourceLink
    On This Page
    Covered Indications and Authorization CriteriaAuthorization, Documentation, and Denial RisksTherapy BackgroundPolicy DefinitionsTreatment Line TerminologyHER2 Biomarker RequirementsCovered Kadcyla Regimens
    There is no evidence of disease progression while on the current regimen.
  1. Confirm recurrent, advanced, or metastatic disease.
  2. Document single-agent use.
  3. Confirm no disease progression on a prior HER2-targeted drug.
  4. Prior Authorization

    Continuation of Therapy

    For continuation authorization, the member must be currently receiving Kadcyla for a diagnosis or condition listed in the coverage criteria and must be receiving benefit from therapy. Benefit requires no unacceptable toxicity and no disease progression on the current regimen.

    • Adjuvant breast cancer treatment is approved for a total of 12 months of therapy.
    • Authorization may be granted for 12 months when all continuation criteria are met.

    Unsupported block type: documentation

    Documentation Required

    Compendia Support for Other Indications

    For an indication not enumerated in the coverage criteria, submit supporting evidence from Medicare-approved compendia with the request.

    • Compendia support is required for indications other than those listed in the policy criteria.
    Denial Risk

    Missing HER2 Documentation

    Failure to provide requested HER2 status documentation may prevent approval of the Kadcyla request.

    • Ensure HER2 status records are available upon request for all submissions.
    Denial Risk

    NSCLC Criteria Not Met

    An HER2-mutated non-small cell lung cancer request may be denied if the disease is not recurrent, advanced, or metastatic; Kadcyla is not being used as a single agent; or the member has progressed on a HER2-targeted drug, including Enhertu or Kadcyla.

    • All NSCLC criteria must be satisfied for approval.
    Denial Risk

    Continuation Criteria Not Met

    Continuation authorization may be denied when the member is not currently receiving Kadcyla, the medication is not treating a diagnosis or condition listed in the coverage criteria, or the member is not benefiting from therapy.

    • Benefit is not established when there is unacceptable toxicity on the current regimen or disease progression on the current regimen.
    • Adjuvant breast cancer treatment cannot exceed a total of 12 months.
    Denial Risk

    Unlisted Indication Review

    An unlisted indication is subject to individual assessment. Requests must include supporting evidence from Medicare-approved compendia; without that evidence, coverage may not be approved.

    • The listed FDA-approved and compendial indications are covered only when all applicable approval criteria are met and no exclusions apply.
    • Indications not enumerated in the coverage criteria are not automatically covered.
    Disease controlThere must be no evidence of disease progression while the member is on the current regimen.
    Other indication
    DefinitionAn indication supported by Medicare-approved compendia when it is not one of the enumerated criteria indications.
    AssessmentAll other indications are assessed on an individual basis.
    Submission requirementRequests for other indications must include supporting evidence from Medicare-approved compendia.
    Subsequent treatment of recurrent, advanced, or metastatic non-small cell lung cancer with a HER2 mutation, using Kadcyla as a single agent, without prior progression on a HER2-targeted drug.
    12 months

    First-line

    Initial brain metastasis treatment: Initial treatment of small asymptomatic brain metastases in HER2-positive breast cancer using Kadcyla as a single agent.12 months
    HER2
    Required biomarkerHER2-positive.
    Applicable indicationRequired for recurrent, unresectable, or metastatic salivary gland tumors.
    Treatment requirementKadcyla must be used as a single agent.